Extract

This was a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. All patients received vismodegib until evidence of progression, intolerable toxicities most probably attributable to vismodegib, or withdrawal from the study.

Inclusion criteria

• Basal Cell Carcinoma

Country

• Australia
• Belgium
• France
• Germany
• United Kingdom
• United States

Links

• ictrp
• nct